Eramet S.A [ERA] vs ZCI Limited [CV] Detailed Stock Comparison
TLDR: Quick Comparison Summary
We found some data (3 metrics), but not enough for a complete comparison. Metrics like P/E ratio, profitability, and financial health are still available in the detailed tabs below.
View Metrics Details
Vital Metrics Comparison
Note: Limited metrics are available for comparison. Check other tabs for more detailed analysis.
| Metric | Eramet S.A. | ZCI Limited | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 105.50 | 2.50 | ZCI Limited |
| Price-to-Book Ratio | 2.08 | N/A | N/A |
| Debt-to-Equity Ratio | 168.90 | N/A | N/A |
| PEG Ratio | 9.08 | N/A | N/A |
| EV/EBITDA | 71.08 | N/A | N/A |
| Profit Margin (TTM) | -17.10% | N/A | N/A |
| Operating Margin (TTM) | -7.74% | N/A | N/A |
| Return on Equity | -31.37% | N/A | N/A |
| Return on Assets (TTM) | -2.06% | N/A | N/A |
| Free Cash Flow (TTM) | $-742.00M | N/A | N/A |
| Dividend Yield | 3.15% | N/A | N/A |
| 1-Year Return | 20.63% | 0.00% | Eramet S.A. |
| Price-to-Sales Ratio (TTM) | 0.54 | N/A | N/A |
| Enterprise Value | $4.19B | $0 | Eramet S.A. |
| EV/Revenue Ratio | 1.50 | N/A | N/A |
| Revenue per Share (TTM) | $97 | N/A | N/A |
| Earnings per Share (Diluted) | $-16.67 | N/A | N/A |
| Beta (Stock Volatility) | 0.91 | N/A | N/A |
Eramet S.A. vs ZCI Limited Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eramet S.A. | -3.90% | 3.92% | -4.85% | 6.38% | 7.33% | -13.96% |
| ZCI Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eramet S.A. | 20.63% | -39.50% | 9.75% | 94.53% | -35.78% | -35.78% |
| ZCI Limited | 0.00% | 0.00% | 0.00% | 0.00% | -31.03% | -31.03% |
Performance & Financial Health Analysis: Eramet S.A. vs ZCI Limited
| Metric | ERA | CV |
|---|---|---|
| Market Information | ||
| Market Cap | €1.60B | €11.14M |
| Market Cap Category | Large cap | Small cap |
| 10 Day Avg. Volume | 34,815 | N/A |
| 90 Day Avg. Volume | 47,275 | N/A |
| Last Close | €53.00 | €0.20 |
| 52 Week Range | €44.50 - €88.20 | €0.20 - €0.20 |
| % from 52W High | -39.91% | 0.00% |
| All-Time High | €167.20 (Apr 16, 2018) | €0.29 (Jul 14, 2014) |
| % from All-Time High | -68.30% | -31.03% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.08% | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -0.17% | N/A |
| Operating Margin (TTM) | -0.08% | N/A |
| Return on Equity (TTM) | -0.31% | N/A |
| Debt to Equity (MRQ) | 168.90 | N/A |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €25.19 | N/A |
| Cash per Share (MRQ) | €20.77 | N/A |
| Operating Cash Flow (TTM) | €-313,000,000 | €0 |
| Levered Free Cash Flow (TTM) | €-493,124,992 | €0 |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.15% | N/A |
| Last 12-Month Dividend | €1.51 | N/A |
Valuation & Enterprise Metrics Analysis: Eramet S.A. vs ZCI Limited
| Metric | ERA (Apr 24, 2026) | CV (Apr 11, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 105.50 | 2.50 |
| Forward P/E | 9.08 | N/A |
| PEG Ratio | 9.08 | N/A |
| Price to Sales (TTM) | 0.54 | N/A |
| Price to Book (MRQ) | 2.08 | N/A |
| Market Capitalization | ||
| Market Capitalization | €1.60B | €11.14M |
| Enterprise Value | €4.19B | €0 |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.50 | N/A |
| Enterprise to EBITDA | 71.08 | N/A |
| Risk & Other Metrics | ||
| Beta | 0.91 | N/A |
| Book Value per Share (MRQ) | €25.19 | N/A |
Financial Statements Comparison: Eramet S.A. vs ZCI Limited
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | ERA (2025) | CV |
|---|---|---|
| Revenue/Sales | 2.75B | N/A |
| Cost of Goods Sold | 1.28B | N/A |
| COGS % of Revenue | 46.6% | - |
| Gross Profit | 1.47B | N/A |
| Gross Margin | 53.4% | - |
| Research & Development | 15.00M | N/A |
| Operating Income (EBIT) | -195.00M | N/A |
| Operating Margin | -7.1% | - |
| EBITDA | 331.00M | N/A |
| EBITDA Margin | 12.0% | - |
| Pre-Tax Income | -525.00M | N/A |
| Pre-Tax Income % of Revenue | -19.1% | - |
| Income Tax | 43.00M | N/A |
| Income Tax % of Revenue | 1.6% | - |
| Net Income (Profit) | -570.00M | N/A |
| Profit Margin | -20.7% | - |
Balance Sheet & Liquidity Metrics
| Metric | ERA (2025) | CV |
|---|---|---|
| Cash & Equivalents | 568.00M | N/A |
| Total Current Assets | 1.98B | N/A |
| Total Current Assets % of Revenue | 71.8% | - |
| Total Current Liabilities | 1.44B | N/A |
| Total Current Liabilities % of Revenue | 52.3% | - |
| Long-Term Debt | 2.03B | N/A |
| Long-Term Debt % of Revenue | 73.7% | - |
| Total Shareholders Equity | 1.50B | N/A |
| Retained Earnings | N/A | N/A |
| Retained Earnings % of Revenue | 0.0% | - |
| Property, Plant & Equipment | 1.78B | N/A |
Cash Flow Statement Comparison
| Metric | ERA (2025) | CV |
|---|---|---|
| Operating Cash Flow | -661.00M | N/A |
| Operating Cash Flow % of Revenue | -24.0% | - |
| Capital Expenditures | -428.00M | N/A |
| Free Cash Flow | -742.00M | N/A |
| FCF Margin | -27.0% | - |
| Debt Repayment | -243.00M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ERA | CV |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 28.50M | 55.68M |
| Float Shares | 18.91M | N/A |
| % Held by Insiders | 69.80% | N/A |
| % Held by Institutions | 15.00% | N/A |
| % Held by Public | 15.20% | N/A |
Dividend Analysis & Yield Comparison: Eramet S.A. vs ZCI Limited
| Metric | ERA | CV |
|---|---|---|
| Last 12-Month Dividend | €1.51 | N/A |
| Last 12-Month Dividend Yield | 3.15% | N/A |
| 3-Year Avg Annual Dividend | €2.17 | N/A |
| 3-Year Avg Dividend Yield | 2.79% | N/A |
| 3-Year Total Dividends | €6.51 | N/A |
| Ex-Dividend Date | Jun 02, 2025 | N/A |